The Promise of Immunotherapy in the Management of Gastrointestinal Cancers: What Does Managed Care Need to Know About Checkpoint Inhibition and Biomarkers in Colorectal and Gastric Tumors 

A continuing medical education activity sponsored by NAMCP and AAMCN

 The Promise of Immunotherapy in the Management of Gastrointestinal Cancers: What Does Managed Care Need to Know About Checkpoint Inhibition and Biomarkers in Colorectal and Gastric Tumors is a 3-part webcast series that will provide attendees with the latest information in the management of Gastrointestinal Cancers.

By clicking on each of the titles, you will be able to participate in each part.
It is not required that you participate in all 3 or in order.

These are archives of live webinars held between March 13, 2019 to March 20, 2019.
If you participated in any of the live webinars, you are not eligible to claim credit from the archive of that webinar.

Each session has its own specific valid dates

This series is supported by an educational grant froM

Merck Sharp & Dohme Corp.

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

 Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.  

 To print or save your certificate, you will need to click on the “download” button and either print or save.

 These presentations require Adobe Flash Player.  You can download it here.

PLEASE CLICK HERE TO VIEW THE PRESENTATION

PLEASE CLICK HERE FOR POST TEST AND EVALUATION

 Description:
Immunotherapy has now become a key component of the treatment arsenal for colorectal and gastric or gastroesophageal junction cancers, and extensive investigations are underway to further refine and expand its role across the spectrum of gastrointestinal (GI) cancers. Identifying the patients most likely to benefit from immune-based therapies is essential for maximizing the potential of checkpoint inhibitors in the management of these tumors, and predictive biomarkers can be useful in this regard.


Part 1
Molecular Complexities and Biomarkers in Gastrointestinal Cancers: Addressing Unmet Needs in the Evolving Paradigm of Immunotherapies

  • Discuss the mechanisms of action of immune checkpoint inhibitors and the rationale for checkpoint inhibition in the treatment of Gastrointestinal (GI) cancers

  • Examine the current guideline recommendations for MSI-H/dMMR testing, as well as implications for treatment selection for patients with metastatic MSI-H/dMMR GI cancers

  • Analyze how current biomarkers for immunotherapy, including MSI-H/dMMR, PD-L1, TMB, and others across the spectrum of GI cancers, may inform treatment choices

  • Explore strategies for the prevention & optimal management of immune-related adverse effects in GI cancers
    Physician, Nursing and CMCN credits valid to April 1, 2020
     

Part 2
A Deeper Look into Checkpoint Inhibitors in the Management of MSI-High Colorectal Cancer: What Does the Latest Evidence Have to Say?

  • Evaluate the safety and efficacy data and evidence for the use of anti–PD-1 immunotherapy in MSI-High metastatic colorectal cancer alone or in combination with other agents, and describe recent clinical data

  • Examine the current guideline recommendations for MSI-H/dMMR testing, as well as implications for treatment selection for patients with metastatic MSI-H/dMMR colorectal cancer

  • Explore strategies for the prevention & optimal management of immune-related adverse effects in metastatic colorectal cancer
    Physician
    , Nursing and CMCN credits valid to April 1, 2020
     

Part 3
The Present and Future of Immunotherapy in Gastrointestinal Cancers: What Does Managed Care Need to Know to Improve Clinical and Economic Outcomes?

  • Evaluate the safety and efficacy data and evidence for the use of immune checkpoint inhibitors in gastrointestinal cancers.

  • Discuss the managed care considerations of current and emerging immunotherapies by exploring where these agents fit into the current GI cancer management paradigm

  • Apply methods to enable optimal cost management of immunotherapies to be realized by multiple GI cancer stakeholders, including managed care organizations
    Physician, Nursing and CMCN credits valid to April 1, 2020